Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Current Assets (2016 - 2025)

Historic Current Assets for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $76.2 million.

  • Aytu Biopharma's Current Assets rose 2091.57% to $76.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $76.2 million, marking a year-over-year change of. This contributed to the annual value of $79.2 million for FY2025, which is 2793.3% up from last year.
  • According to the latest figures from Q4 2025, Aytu Biopharma's Current Assets is $76.2 million, which was up 2091.57% from $81.1 million recorded in Q3 2025.
  • Aytu Biopharma's Current Assets' 5-year high stood at $105.2 million during Q2 2021, with a 5-year trough of $59.9 million in Q2 2022.
  • Its 5-year average for Current Assets is $76.2 million, with a median of $73.6 million in 2022.
  • As far as peak fluctuations go, Aytu Biopharma's Current Assets surged by 3952.69% in 2021, and later tumbled by 4305.17% in 2022.
  • Quarter analysis of 5 years shows Aytu Biopharma's Current Assets stood at $87.5 million in 2021, then fell by 19.34% to $70.6 million in 2022, then increased by 1.08% to $71.4 million in 2023, then decreased by 11.65% to $63.1 million in 2024, then grew by 20.92% to $76.2 million in 2025.
  • Its last three reported values are $76.2 million in Q4 2025, $81.1 million for Q3 2025, and $79.2 million during Q2 2025.